Xtant Medical Q2 FY26 turns to net loss of $9.41 million; revenue drops 34.96% to $23.03 million - XTNT News | RalliesXtant Medical Q2 FY26 turns to net loss of $9.41 million; revenue drops 34.96% to $23.03 million
X
XTNT• Q2 revenue and profit swing lower
- Xtant Medical posted Q2 revenue of $23.03 million, down 34.96% from $35.4 million a year earlier on divestitures and no license revenue.
- Net results swung to a loss of $9.41 million, or $0.07 per share, from profit of $3.6 million, or $0.03 per share.
- Gross margin fell to 57.9% from 68.6%, hit by the end of high-margin Q-code license revenue and inventory charges.
- Non-GAAP adjusted EBITDA swung to a loss of $2.7 million from a gain of $6.9 million, reflecting a $5 million Dilon exclusivity fee.
Distribution deal, product launch, and outlook cut
- The company signed an exclusive U.S. distribution deal for Dilon’s HEMOBLAST Bellows, hiring its 20-person sales team.
- Xtant also launched Trivium Shaped.
•
